Cargando…

Progress and Future Directions with Peptide-Drug Conjugates for Targeted Cancer Therapy

We review drug conjugates combining a tumor-selective moiety with a cytotoxic agent as cancer treatments. Currently, antibody-drug conjugates (ADCs) are the most common drug conjugates used clinically as cancer treatments. While providing both efficacy and favorable tolerability, ADCs have limitatio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lindberg, Jakob, Nilvebrant, Johan, Nygren, Per-Åke, Lehmann, Fredrik
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8512983/ https://www.ncbi.nlm.nih.gov/pubmed/34641586 http://dx.doi.org/10.3390/molecules26196042

Ejemplares similares

Lysis of Staphylococcal Cells by Modular Lysin Domains Linked via a Non-covalent Barnase-Barstar Interaction Bridge
por: Hjelm, Linnea C., et al.
Publicado: (2019)

Learn from antibody–drug conjugates: consideration in the future construction of peptide-drug conjugates for cancer therapy
por: Wu, Mo, et al.
Publicado: (2022)

Assigned NMR backbone resonances of the ligand-binding region domain of the pneumococcal serine-rich repeat protein (PsrP-BR) reveal a rigid monomer in solution
por: Schulte, Tim, et al.
Publicado: (2020)

Peptide-Drug Conjugates and Their Targets in Advanced Cancer Therapies
por: Hoppenz, Paul, et al.
Publicado: (2020)

Antibody-Drug Conjugates for Breast Cancer Treatment: Emerging Agents, Targets and Future Directions
por: Yang, Tinglin, et al.
Publicado: (2023)

Peptide Drug Conjugates and Their Role in Cancer Therapy
por: Heh, Ethan, et al.
Publicado: (2023)

Melflufen - a peptidase-potentiated alkylating agent in clinical trials
por: Wickström, Malin, et al.
Publicado: (2017)

NGR-peptide−drug conjugates with dual targeting properties
por: Enyedi, Kata Nóra, et al.
Publicado: (2017)

Kinase-targeted cancer therapies: progress, challenges and future directions
por: Bhullar, Khushwant S., et al.
Publicado: (2018)

CD44v6-Targeted Imaging of Head and Neck Squamous Cell Carcinoma: Antibody-Based Approaches
por: Spiegelberg, Diana, et al.
Publicado: (2017)

Antibody–Drug Conjugates in Breast Cancer: Current Status and Future Directions
por: Mark, Cynthia, et al.
Publicado: (2023)

Applications of Cell-Penetrating Peptides for Tumor Targeting and Future Cancer Therapies
por: Regberg, Jakob, et al.
Publicado: (2012)

Targeting the Gastrin-Releasing Peptide Receptor (GRP-R) in Cancer Therapy: Development of Bombesin-Based Peptide–Drug Conjugates
por: Gomena, Jacopo, et al.
Publicado: (2023)

Recent progress of aptamer‒drug conjugates in cancer therapy
por: He, Jiaxuan, et al.
Publicado: (2023)

Gemcitabine Peptide-Based Conjugates and Their Application in Targeted Tumor Therapy
por: Hawryłkiewicz, Aleksandra, et al.
Publicado: (2021)

Development of novel bone targeting peptide–drug conjugate of 13-aminomethyl-15-thiomatrine for osteoporosis therapy
por: Su, Jia, et al.
Publicado: (2021)

Peptide–drug conjugates (PDCs): a novel trend of research and development on targeted therapy, hype or hope?
por: Fu, Chen, et al.
Publicado: (2023)

Novel Peptide-drug Conjugate Melflufen Efficiently Eradicates Bortezomib-resistant Multiple Myeloma Cells Including Tumor-initiating Myeloma Progenitor Cells
por: Byrgazov, Konstantin, et al.
Publicado: (2021)

On the design principles of peptide–drug conjugates for targeted drug delivery to the malignant tumor site
por: Vrettos, Eirinaios I, et al.
Publicado: (2018)

Research advances in peptide‒drug conjugates
por: Gong, Liming, et al.
Publicado: (2023)

Gene Therapy 2017: Progress and Future Directions
por: Keeler, AM, et al.
Publicado: (2017)

Melflufen, a peptide‐conjugated alkylator, is an efficient anti‐neo‐plastic drug in breast cancer cell lines
por: Schepsky, Alexander, et al.
Publicado: (2020)

Antibody-drug conjugates: Present and future
por: Beck, Alain, et al.
Publicado: (2013)

Photosensitizer and peptide-conjugated PAMAM dendrimer for targeted in vivo photodynamic therapy
por: Narsireddy, Amreddy, et al.
Publicado: (2015)

EDB-FN Targeted Peptide–Drug Conjugates for Use against Prostate Cancer
por: Park, Shang Eun, et al.
Publicado: (2019)

Gold nanoparticles stabilize peptide-drug-conjugates for sustained targeted drug delivery to cancer cells
por: Kalimuthu, Kalishwaralal, et al.
Publicado: (2018)

Molecular Engineering of Peptide–Drug Conjugates for Therapeutics
por: Fang, Yu, et al.
Publicado: (2022)

Antiviral Peptide-Based Conjugates: State of the Art and Future Perspectives
por: Todorovski, Toni, et al.
Publicado: (2023)

Research Progress of Antibody–Drug Conjugate Therapy for Advanced Gastric Cancer
por: Wang, Na, et al.
Publicado: (2022)

Application of triple quadrupole mass spectrometry for the characterization of antibody–drug conjugates
por: Källsten, Malin, et al.
Publicado: (2019)

The albumin-binding domain as a scaffold for protein engineering
por: Nilvebrant, Johan, et al.
Publicado: (2013)

Novel peptide–dendrimer conjugates as drug carriers for targeting nonsmall cell lung cancer
por: Liu, Jianfeng, et al.
Publicado: (2011)

Antibody drug conjugate: the “biological missile” for targeted cancer therapy
por: Fu, Zhiwen, et al.
Publicado: (2022)

Aptamer nucleotide analog drug conjugates in the targeting therapy of cancers
por: Li, Yongshu, et al.
Publicado: (2022)

Antibody-drug conjugates: the paradigm shifts in the targeted cancer therapy
por: Aggarwal, Devesh, et al.
Publicado: (2023)

Advances in Targeted Therapy of Breast Cancer with Antibody-Drug Conjugate
por: Subhan, Md Abdus, et al.
Publicado: (2023)

Development of Photoremovable Linkers as a Novel Strategy to Improve the Pharmacokinetics of Drug Conjugates and Their Potential Application in Antibody–Drug Conjugates for Cancer Therapy
por: Johan, Audrey Nathania, et al.
Publicado: (2022)

A “ligand-targeting” peptide-drug conjugate: Targeted intracellular drug delivery by VEGF-binding helix-loop-helix peptides via receptor-mediated endocytosis
por: Michigami, Masataka, et al.
Publicado: (2021)

An affibody-adalimumab hybrid blocks combined IL-6 and TNF-triggered serum amyloid A secretion in vivo
por: Yu, Feifan, et al.
Publicado: (2014)

The Peptide–Drug Conjugate Melflufen Modulates the Unfolded Protein Response of Multiple Myeloma and Amyloidogenic Plasma Cells and Induces Cell Death
por: Flanagan, Ken, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_oi5tdkfiqvqb1pfj2171lju44d